aap Implantate (AAQ1) AI Stock Analysis

aap Implantate

(XETRA:AAQ1)

Select Model

Rating:43Neutral

Price Target:EUR 1.50▲(3.45% Upside)

Action:reiterated

Date:08/30/26

The score is held down primarily by persistent net losses and ongoing cash burn, which outweigh strong gross margins and a relatively manageable leverage profile. Technically, the stock is in a downtrend (below major moving averages with negative MACD), adding risk. Valuation offers limited support because earnings are negative and no dividend yield is indicated.

Positive Factors

Strong Gross MarginAn approximately 82% gross margin indicates strong product-level economics in the orthopedic implant business. This provides a meaningful base for covering operating costs and funding commercial activity, while also leaving potential for improved earnings if the company can achieve better cost discipline and scale.

Negative Factors

Persistent UnprofitabilityPersistent net losses show that strong gross profitability has not yet translated into a self-sustaining earnings model. Continued operating losses can consume equity, restrict investment capacity, and leave the company dependent on future operational improvement or external funding to support its strategy.

aap Implantate (AAQ1) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 21.34M
Dividend Yield: ―
Average Volume (3M): 1,632
Price to Earnings (P/E): -7.4
Beta (1Y): -0.13
Revenue Growth: 1.81%
EPS Growth: 42.09%
Country: Germany
Employees: 105
Sector: General
Sector Strength: 55
Industry: Medical - Specialties

aap Implantate Business Overview & Revenue Model

Company Description

Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international reg...

How the Company Makes Money

aap Implantate generates revenue primarily by selling orthopedic/trauma implant systems and associated surgical instrumentation to healthcare providers (such as hospitals and surgical centers), either directly or via distribution partners. Key revenu...

aap Implantate Financial Statement Overview

Summary

Despite very strong gross margins (~82%), the company remains structurally unprofitable with persistent net losses. Cash generation is weak with consistently negative operating cash flow and free cash flow (TTM operating cash flow roughly -€1.3M), implying ongoing funding needs. The balance sheet looks relatively conservative (low debt-to-equity ~0.11 and positive equity), but continued losses and negative ROE (TTM ~-29%) are a material drag.

Income Statement

26Negative

Balance Sheet

58Neutral

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Jun 2025	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.78M	12.50M	12.20M	11.48M	11.52M	12.17M
Gross Profit	11.38M	10.80M	10.67M	9.74M	10.58M	2.32M
EBITDA	-815.20K	-632.00K	-1.19M	-3.43M	-1.57M	-520.00K
Net Income	-2.73M	-2.60M	-3.63M	-5.13M	-2.56M	-2.52M
Balance Sheet
Total Assets	16.11M	13.75M	15.84M	19.47M	20.23M	22.95M
Cash, Cash Equivalents and Short-Term Investments	286.00K	1.40M	2.46M	1.64M	236.00K	2.11M
Total Debt	3.97M	984.00K	1.72M	5.29M	3.17M	5.08M
Total Liabilities	7.93M	5.06M	5.38M	8.63M	7.40M	10.18M
Stockholders Equity	8.18M	8.70M	10.46M	10.85M	12.83M	12.78M
Cash Flow
Free Cash Flow	-1.78M	-2.16M	-1.45M	-3.40M	-2.38M	-2.99M
Operating Cash Flow	-1.33M	-1.43M	-1.12M	-2.99M	-1.89M	-2.47M
Investing Cash Flow	-876.00K	-670.00K	-327.00K	-397.00K	-469.00K	155.00K
Financing Cash Flow	2.27M	859.00K	2.22M	4.42M	475.00K	3.53M

aap Implantate Technical Analysis

Technical Analysis SentimentNegative

Last Price1.45

Price Trends

50DMA1.60Negative

100DMA1.61Negative

200DMA1.64Negative

Market Momentum

MACD-0.04Negative

RSI37.36Neutral

STOCH62.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:AAQ1, the sentiment is Negative. The current price of 1.45 is below the 20-day moving average (MA) of 1.50, below the 50-day MA of 1.60, and below the 200-day MA of 1.64, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 37.36 is Neutral, neither overbought nor oversold. The STOCH value of 62.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:AAQ1.

aap Implantate Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:AAQ1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DE:AFX	73Outperform	EUR 3.13B	20.95	5.52%	1.57%	-0.06%	-38.81%
DE:EUZ	69Neutral	EUR 832.23M	16.63	19.49%	1.65%	4.42%	35.68%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:GME	46Neutral	EUR 11.71M	-15.40	-4.38%	4.65%	1.58%	-148.73%
DE:AAQ1	43Neutral	EUR 21.34M	-7.44	-32.36%	―	1.81%	42.09%

* General Sector Average

Performance Comparison

DE:AAQ1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:AAQ1	aap Implantate	1.45	-0.01	-0.68%
DE:AFX	Carl Zeiss Meditec	34.98	-7.07	-16.82%
DE:EUZ	Eckert & Ziegler Strahlen und Medizintechnik	13.30	-3.09	-18.88%
DE:GME	Geratherm Medical	2.15	-1.52	-41.40%
DE:MF6	MagForce AG	―	―	―
DE:E8X	elexxion AG	0.01	-0.13	-90.71%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 30, 2026

aap Implantate AI Stock Analysis